Navigation Links
BioMS Medical Announces Third Quarter 2008 Results
Date:11/6/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 6 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the third quarter ended September 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing dirucotide (MBP8298), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the U.S.

"The third quarter saw positive developments in the dirucotide development plan, with completion of the interim analysis resulting in a significant milestone payment from our partner Lilly," said Kevin Giese, President and CEO of BioMS Medical. "Dirucotide was also granted fast track designation by the U.S. FDA, another important achievement which could potentially accelerate the development and review process for this important MS drug."

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for dirucotide (MBP8298):

- MAESTRO-01: A randomized, double-blind pivotal phase II/III trial in

Canada and Europe evaluating dirucotide (MBP8298) for the treatment

of secondary progressive MS (SPMS). The study has completed full

recruitment of 611 patients at 47 trial sites in 9 countries. To

date, there have been nine positive safety reviews from the Data

Safety Monitoring Board (DSMB). Full analysis of this trial is

expected in the second half of 2009.

- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal

trial. Eligible patients who have successfully completed the blinded,

placebo controlled MAESTRO-01 trial may choose to receive dirucotide

(MBP8298) on an un-blinded basis. To date, approximately 95% of

patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02.

- MAESTRO-03: A U.S. pivotal phase III trial evaluatin
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... scientific journal, Expert Opinion on Biological Therapy , ... Zhenggang Zhang , at the Henry Ford Hospital ... Thymosin beta 4 (TB4) has the capacity to promote ... or more post-injury, leading to neurological recovery in each ...
(Date:3/3/2015)... CARLOS, Calif. , March 3, 2015  Rosa ... expertise in drug-disease modeling and simulation research, today announced ... the 2015 American Society for Clinical Pharmacology and Therapeutics ... March 3-7 2015.   Logo - ... and Rosa will present a poster describing a quantitative ...
(Date:3/3/2015)... 3, 2015 Kindred Biosciences, Inc. (NASDAQ: ... the lives of pets, announced today that it will release ... 12, 2015 after the market close. The Company will host ... Interested parties may access the call by ... internationally, and using conference ID 98449349.  The ...
(Date:3/3/2015)... Genedata, a leading provider of advanced ... research, today announced that Pfizer Inc. has licensed ... at Pfizer biopharma research and development sites in ... global deployment and roll out project at Pfizer’s ... (CTI), and Pharmaceutical Sciences groups. , “Pfizer ...
Breaking Biology Technology:Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3
... 2 The Foundation for,Biomedical Research (FBR) congratulates ... DeBakey the highest civilian honor it can bestow, ... to cardiovascular medicine,have improved the health of millions ... extraordinary talents as a surgeon, inventor, educator and,medical ...
... Roche Files CTA for Third Genmab Antibody,Summary: Genmab,s Partner Roche has ... ... Genmab Antibody, COPENHAGEN, October 2 Genmab ... Clinical Trial,Application (CTA) with the British Medicines and Healthcare products,Regulatory Agency ...
... N.J., Oct. 2 Synvista Therapeutics,Inc. (Amex: SYI ... Chief Executive Officer will present at the BIO InvestorForum,2007 ... BIO InvestorForum will,be held on October 9 - 11, ... Dr. Berkowitz will discuss the company,s planned and/or ...
Cached Biology Technology:Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal 2Genmab A/S - Company Announcement 2Synvista Therapeutics to Present at the BIO InvestorForum 2007 2Synvista Therapeutics to Present at the BIO InvestorForum 2007 3
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
(Date:2/5/2015)... Calif. , Feb. 3, 2015 ... technology, demand from industries such as consumer electronics, ... market for surface mount technology (SMT) screen printers. ... to automatic control will push the adoption curve ... will remain steady as glue dispensers are indispensable ...
(Date:1/22/2015)... Technology Showcase, Hall E -   EyeLock Inc. , ... it will showcase its EyeLock ID technology integrated in a ... Energy,s Oak Ridge National Laboratory (ORNL) at the ... identity authentication technology is being used to validate the driver ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... Va.Coinciding with the observance of Nuclear Medicine Week (October ... (October), SNM released today a new fact sheet highlighting ... improving the ways in which breast cancer is diagnosed ... effective, safe and painless imaging tool for diagnosing and ...
... a study in mice has found that inactivating a ... increase energy expenditure and help lower diet-induced obesity. These ... might lead to some new roads in weight-loss ... to continually "burn fat" in order to maintain body ...
... of spring: a swarm of bees on the move. But how ... of the community know the way remains a mystery. Curious to ... homes, Tom Seeley, a neurobiologist from Cornell University, and engineers Kevin ... to find out how swarms are guided to their new home ...
Cached Biology News:SNM releases new fact sheet on breast cancer and molecular imaging 2Making metabolism more inefficient can reduce obesity 2Bee swarms follow high-speed 'streaker' bees to find a new nest 2
... designed for easy transformation of the budding ... successful transformation simply by mixing a plasmid ... yeast cells. No complicated steps, such as ... kit is particularly well suited for high-throughput ...
... system, offers fast and reliable batch processing ... Ultra Evolution , SAFIRE monochromator reader , ... , LS Series of Laser Scanners , ... range of detection and separation systems, Connect ...
... STag Purification Kits enable rapid analytical to ... proteins produced from appropriate vectors. Sufficient reagents ... 1 mg target protein under native or ... S-protein Agarose, which specifically retains STag fusion ...
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
Biology Products: